Atossa Therapeutics Announces Participation in Virtual Summit
Atossa Therapeutics to Join the 2024 Maxim Healthcare Summit
SEATTLE — Atossa Therapeutics, Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company committed to developing innovative solutions in oncology, has exciting news to share. The company has announced that Michael Parks, the Vice President of Investor and Public Relations, will take part in a virtual fireside chat during the 2024 Maxim Healthcare Virtual Summit.
Event Details and Participation
This engaging session is scheduled for Wednesday, October 16, 2024, at 12:00 p.m. EDT. Through this platform, Atossa aims to connect with a wider audience interested in their pioneering efforts in the field of cancer treatment, particularly focusing on breast cancer.
Innovative Developments in Oncology
Atossa Therapeutics has dedicated its resources to addressing significant unmet medical needs within oncology. Their research is centered around (Z)-endoxifen, which is being explored for its potential to prevent and treat breast cancer. This innovative approach reflects Atossa's commitment to enhancing patient care and advancing treatment options.
Accessing the Live Webcast
For those eager to learn more, the live webcast for the event will be accessible to interested parties. Registration for the conference will provide the chance to gain insights directly from Atossa’s leadership on their current projects and future aspirations within the biopharmaceutical industry.
About Atossa Therapeutics, Inc.
Atossa Therapeutics, Inc. is at the forefront of developing transformative treatments for cancer patients. Their focus on breast cancer positions them uniquely in the market, as they leverage groundbreaking research to potentially revolutionize treatment protocols. The company is devoted to refining their product pipeline to provide effective and innovative cancer therapies.
Contact Information
If you wish to learn more about Atossa Therapeutics or have specific inquiries, Michael Parks, the Vice President of Investor and Public Relations, is available for contact. He can provide additional information about the company’s initiatives and its impact on oncology research.
Contact:
Michael Parks
Vice President, Investor and Public Relations
484-356-7105
michael.parks@atossainc.com
Frequently Asked Questions
What is Atossa Therapeutics focusing on in their research?
Atossa Therapeutics is primarily focused on developing treatments for breast cancer using (Z)-endoxifen.
When will the virtual summit take place?
The 2024 Maxim Healthcare Virtual Summit will occur on October 16, 2024, at 12:00 p.m. EDT.
Who is representing Atossa at the summit?
Michael Parks, the Vice President of Investor and Public Relations, will represent Atossa Therapeutics at the summit.
How can I access the virtual summit?
Interested individuals can register for the event to access the live webcast via the conference website.
What is Atossa's commitment in the pharmaceutical industry?
Atossa is dedicated to addressing unmet medical needs in oncology, focusing on innovative solutions for cancer treatment.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.